Hematopoietic stem cells (HSCs) originate during embryonic life in association with arterial vessels including the aorta in the aorta/gonad/mesonephros (AGM) region and the umbilical and vitelline arteries ([@bib6]). The first HSCs are detected around embryonic day (E) 10 of mouse development in hematopoietic clusters emerging from the ventral wall of the aorta in the AGM and are defined by their unique capacity to reconstitute hematopoiesis of immunodepleted adult recipients in transplantation assays. The Notch pathway is required for HSC development in the vertebrate embryo, upstream of Runx1 ([@bib4]) and GATA-2 ([@bib30]), but is dispensable for yolk sac (YS) primitive hematopoiesis ([@bib31]; [@bib2]; [@bib3]). Importantly, *Gata2* but not *Runx1* expression was totally impaired in the aorta of *Jag1^−/−^* mutant mouse embryos, which fail to generate hematopoiesis ([@bib30], [@bib32]). Re-expression of GATA-2 partially rescued generation of hematopoietic cells from *Jag1^−/−^* AGM cells ([@bib32]), consistent with its pivotal role in definitive embryonic and adult hematopoiesis ([@bib37]).

The Notch signaling pathway and its function in controlling cell fate diversification is conserved through evolution. Notch receptors interact with their ligands that are expressed on neighboring cells, and this interaction induces two sequential proteolytic events, which release the intracellular Notch (ICN) fragment. Once activated, Notch associates with its specific coactivator Mastermind (Mam) and the nuclear factor RBPJ to induce a transcriptional response, generally associated with the inhibition of a particular cell fate destiny from a population of equivalent cells ([@bib18]). Classical examples of Notch-dependent fate inhibition are B cell differentiation in the hematopoietic system, secretory lineage in the adult intestine, and the neural fate from neural/glial precursors. Most of these Notch responses are context dependent and associated with regulation of tissue-specific targets; however, a group of Notch target genes belonging to the *Hairy/Enhancer of split* (*HES*) family are known to mediate Notch actions in a wide range of cell types and organisms ([@bib14]). We previously found that activation of Notch in the AGM was concomitant with the transcriptional expression of *Hes1* and *Hes-related* family genes ([@bib30]).

HES proteins are bHLH transcriptional repressors including the Notch targets HES-1, HES-3, HES-5, HES-7, and the HES-related proteins HRT-1 and HRT-2 ([@bib14]). In the hematopoietic system, HES-1 has a major function in normal T cell development, but it is also directly involved in the maintenance of Notch-induced T cell leukemias ([@bib36]; [@bib7]; [@bib38]). In addition, ectopic HES-1 inhibits differentiation of bone marrow HSCs when cultured in vitro ([@bib20]); however, nothing is known about a putative role of HES in regulating embryonic hematopoiesis or HSC generation. In this study, we investigate the mechanisms that control HSC development downstream of Notch and demonstrate that HES repressors are essential for regulating the levels of *Gata2* in the AGM precursors and generate functional hematopoietic cells.

RESULTS
=======

Increased hematopoietic cluster emergence in *Hes*-deficient embryonic aortas
-----------------------------------------------------------------------------

*Hes1* is expressed in the aortic endothelium and the presumptive hematopoietic clusters of the AGM region ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib32]), suggestive of a hematopoietic function. However, *Hes1*-null embryos contain functional HSCs and progenitors in the fetal liver that are able to reconstitute all hematopoietic lineages except T cells when transplanted into RAG2-null mice. We explored the possibility that other *Hes* members compensate for *Hes1* deficiency during hematopoietic development, similarly to what occurs in the nervous system ([@bib29]). To this purpose, we used two genetic models, the first one carrying a constitutive deletion of *Hes1* and *Hes5* alleles in different combinations and the second with constitutive deletion of one or two copies of *Hes5* combined with *Hes1*-loxP alleles, which can be deleted after tamoxifen treatment when crossed with mice carrying the *β-actin--CRE-ERT* transgene. We first determined whether deletion of several *Hes1* and *Hes5* alleles in the AGM affects the expression of other members of this family of repressors. Importantly we found that *Hes5*, which is not detected in the endothelium nor hematopoietic clusters of wild-type AGM ([Fig. 1 A](#fig1){ref-type="fig"}), was highly induced in both tissues after genetic deletion of *Hes1* ([Fig. 1, B and C](#fig1){ref-type="fig"}). In contrast, other *Hes* family genes such as *Hrt1/Hey1* and *Hrt2/Hey2* were not affected ([Fig. 1 B](#fig1){ref-type="fig"}). Notch activity but also HRT-1 and HRT-2 functions are essential to induce the arterial program ([@bib9]), which constitutes the niche for HSC generation. Thus, we tested whether combined *Hes1/5* deficiency precludes arterial development in the AGM. Analysis of E10.5 embryo sections stained with the pan-endothelial/hematopoietic CD31 marker did not reveal any apparent vascular abnormality in the AGM aorta at this stage ([Fig. 1 F](#fig1){ref-type="fig"} and not depicted). Moreover, by immunostaining and quantitative RT-PCR (qRT-PCR), we found that different arterial-associated genes including *EphrinB2* and *SMA* remained unaffected in these mutant embryos ([Fig. 1, D and E](#fig1){ref-type="fig"}). These results indicate that HES repressors are dispensable for maintaining the arterial program in the embryo. A more accurate analysis of the AGM aorta stained for CD31 (labeling endothelial and hematopoietic cells) demonstrated that *Hes1^−/−^Hes5^+/−^* and *Hes1^−/−^Hes5^−/−^* mutant embryos have larger hematopoietic cluster structures when compared with wild-type embryos ([Fig. 1 F](#fig1){ref-type="fig"}). We confirmed the hematopoietic nature of these clusters by staining with anti--C-Kit (not depicted) and CD41 ([Fig. 1 F](#fig1){ref-type="fig"}). Quantification of CD41^+^ cells in the AGM from different wild-type and mutant embryos demonstrated that the number of *Hes1* and *Hes5* deleted alleles inversely correlated with the total number of hematopoietic progenitors per AGM present in the aortic endothelium (up to 10-fold; Spearman's correlation, P \< 0.001; [Fig. 1 G](#fig1){ref-type="fig"}) and the number of enlarged clusters with more than four cells (Spearman's correlation, P = 0.004; [Fig. 1 H](#fig1){ref-type="fig"}), indicating functional compensation between Hes1 and Hes5 in the AGM.

![**Increased hematopoietic cluster emergence in *Hes*-deficient embryonic aortas.** (A) Transversal sections of embryos at 10.5 d showing expression of *Hes5* and *Hes1* by in situ hybridization (ISH). Arrowheads indicate the structures (Ao, aorta; IAHC, intra-aortic hematopoietic cluster; m, mesonephros; nt, neural tube; p2, p2 neural progenitors; SG, sympathetic ganglia). Details of IAHC and aorta in the right panels correspond to the boxed areas in the middle panels. (B) Relative expression of the indicated genes from E10.5 dissected AGMs after 3 d of 4-OH-tamoxifen treatments in explant cultures by qRT-PCR. Fold increase to the wild-type control after *β2-Microglobulin* and *GAPDH* normalization. Bars represent the mean ± SD determination from two experiments showing the fold increase versus the wild-type AGM. (C) Relative expression of *Hes5* from sorted populations (endothelial, CD31^−^C-Kit^−^CD45^−^; hematopoietic clusters, CD31^+^C-Kit^+^) by qRT-PCR. mRNA was extracted from a pool of 10 AGMs at E10.5 in *Hes1^+/+^ Hes5^+/+^* determinations and 4 AGMs in *Hes1^f/f^ Hes5^+/−^ β-ACTIN--CRE-ERT* after in vivo tamoxifen induction at E8. Bars represent the mean ± SD determination from one representative of two experiments showing the fold increase versus the wild-type AGM after β2-Microglobulin normalization. (D) Representative immunostaining of CD44 and SMA (arterial markers) in the AGM region in wild-type or *Hes* mutant embryos on E10.5 (A, dorsal aorta; Ao, aorta in AGM region; cv, cardinal vein; m, mesonephros; nt, neural tube). (E) Relative expression of endothelial (*PECAM1*), arterial markers (EphrinB2, smooth muscle actin \[SMA\], and CD44), and vein marker (EphB4) in E10.5 AGM after 3 d of 4-OH-tamoxifen treatment in explant culture from embryos with the indicated genotypes (*n* = 3 each genotype) by qRT-PCR. Bars represent the mean ± SD determination from three experiments showing the fold increase relative to the wild-type AGM. (F) Representative immunostaining of CD31 (endothelial and hematopoietic) and CD41 (hematopoietic precursors) in the AGM region in wild-type or *Hes* mutant embryos. Arrowheads indicate the structures. Bars: (A and D) 200 µm; (F) 50 µm. (G) Quantification of CD41^+^ cells per micrometer of AGM. Spearman test was used to assess the significance between wild-type allele number and CD41^+^ cells per micrometer. Correlation between number of wild-type alleles and CD41^+^ cells per micrometer was significant (\*\*, P \< 0.001; and ρ = 0.985). Bars represent the mean of counted cells in two different embryos ± SEM. (H) CD41^+^ clusters containing more than four cells per micrometer of AGM. Quantification of CD41^+^ cells per micrometer of AGM. Spearman correlation was used to assess the significance between number of wild-type alleles and CD41^+^ clusters containing more than four cells per micrometer (\*\*, P = 0.005; and ρ = 0.803). Bars represent the mean of counted clusters in two different embryos ± SEM.](JEM_20120993R_Fig1){#fig1}

Occupancy of the *Gata2* promoter by HES-1 and Notch/RBPJ
---------------------------------------------------------

Next, we determined the expression levels of different hematopoietic transcription factors in the AGM clusters from wild-type and mutant embryos. We found that *Runx1*, *c-myb*, and *Gata2* were significantly overexpressed in *Hes*-deficient embryos compared with the wild type (or deletion of one *Hes* allele; [Fig. 2 A](#fig2){ref-type="fig"}). Importantly, expression levels of *Gata2* but not of *Runx1* and *c-myb* in the embryonic AGM directly and significantly correlated with the number of deleted *Hes1/5* alleles in the mutants (Spearman's correlation, P \< 0.001; [Fig. 2 A](#fig2){ref-type="fig"}). Increase in *Gata2* levels was also detected by in situ hybridization of the whole AGM region of *Hes1^−/−^Hes5^+/−^* embryos. Specifically, *Gata2* mRNA was up-regulated in the hematopoietic clusters, mesenchyme, mesonephros, urogenital ridge, and mesentery lining of these mutant embryos when compared with the wild type ([Fig. 2 B](#fig2){ref-type="fig"}).

![**Occupancy of the *Gata2* promoter by HES-1 and Notch/RBPJ.** (A) Relative expression of the indicated genes from E10.5 AGM after 3 d of 4-OH-tamoxifen treatments in explant cultures by qRT-PCR. Fold increase relative to the wild-type control after *β2-Microglobulin* and *GAPDH* normalization. Spearman test was used to assess the significance between number of wild-type alleles and gene expression indicated on the top of the figure. Correlation between number of wild-type *Hes* alleles and *Gata2* expression was significant (P ≤ 0.001 and ρ = 0.985) but not for *c-Myb* (P = 0.126 and ρ = 0.985) and Runx1 expression (P = 0.072 and ρ = 0.591). The mRNA levels of *Runx1*, *Gata2*, and *c-Myb* are significantly up-regulated in cells with three to four deleted compared with zero to one deleted hes alleles (Student's *t* test, P \< 0.05). Bars represent the mean ± SD fold increase determination from two independent experiments. (B) Representative in situ hybridization of *Gata2* in the wild-type (*n* = 2) or *Hes* mutant embryos (*n* = 2, each genotype). Images show transversal section of E10.5 embryos in the AGM region. Arrowheads indicate the structures (Ao, aorta; IAHC, intra-aortic hematopoietic cluster; m, mesonephros; nt, neural tube). Details of IAHC in the right panels correspond to the boxed areas in the left panels. Bars: (left) 200 µm; (right) 20 µm. (C) Graphical representation of the mouse *Gata2* promoter showing the putative RBPJ- or HES-binding consensus found by bioinformatic analysis. Asterisks indicate the conserved sites in the human *Gata2* locus (*IS*, specific promoter; *IG*, general promoter). (D) Sequence and location of the human and mouse conserved RBPJ- and HES-binding sites relative to *IS* and *IG* promoters. (E) ChIP with the anti--HES-1, anti-ICN1, anti-RBPJ, and anti-IgG antibodies from myeloid 32D cells and analysis of the *Gata2* locus by qPCR. One representative of two experiments is shown. (F and G) ChIP with the anti--HES-1, anti-ICN1, anti-RBPJ, and anti-IgG antibodies from E10.5 AGM cells and analysis of the *Gata2* locus by qPCR. One representative from three experiments is shown. (E--G) Error bars represent SD from qPCR values.](JEM_20120993R_Fig2){#fig2}

Previous data from our group indicated that *Gata2* is a downstream target of Notch in the AGM ([@bib30]). By sequence analysis of the *Gata2* locus using Genomatix software, we have now identified the presence of two RBPJ and three HES motifs that are conserved in both the human and mouse *Gata2* gene ([Fig. 2, C and D](#fig2){ref-type="fig"}). Because HES-1 is the main Notch target and a well-characterized transcriptional repressor, we hypothesized that Notch might activate *Gata2* transcription that is next antagonized by Notch-mediated induction of HES-1. To address this possibility, we first conducted chromatin immunoprecipitation (ChIP) analysis using 32D myeloid progenitor cells to determine the recruitment of RBPJ, ICN1, and HES-1 proteins to the *Gata2* locus. We tested *Gata2* occupancy using primers that amplify 15 regions spanning from −3033 to 5827 relative to the TSS at the *IS* promoter ([Fig. 2 E](#fig2){ref-type="fig"}). Of note, *Gata2* can be transcribed from two different promoters (*IS* and *IG*), both yielding the same protein but using a different first untranslated exon ([@bib25]), with *IS* being hematopoietic/neural specific ([@bib27]) and *IG* the general *Gata2* promoter. Our analysis revealed RBPJ and ICN1 occupancy in the −800 to 14 region, which contains two of the three predicted RBPJ-binding sites, whereas HES-1 protein was found associated at the 3059 to 5203 region, which contains the three predicted HES-1 sites ([Fig. 2 E](#fig2){ref-type="fig"}). A similar pattern for Notch1, RBPJ, and HES-1 association was detected using dissected AGM tissue ([Fig. 2, F and G](#fig2){ref-type="fig"}) and human K562 myeloerythroid cells (not depicted). Interestingly, we failed to detect RBPJ or HES binding to the *Gata2* promoter in mouse NIH-3T3 fibroblasts (not depicted). These results indicated that RBPJ/Notch proteins occupy the *IS* promoter, whereas HES-1 binds the *IG* promoter of the *Gata2* gene specifically in hematopoietic cells.

HES-1 is a negative regulator of the *Gata2* promoter in hematopoietic cells
----------------------------------------------------------------------------

Previously, we demonstrated that embryos with deficient Notch activity failed to express *Gata2*, and we presented evidence that *Gata2* is a transcriptional Notch target ([@bib30]). However, ectopic expression of ICN1 in AGM cells does not increase *Gata2* transcription (not depicted), which could be explained by a negative regulation of the *Gata2* promoter by HES-1. To test this possibility, we analyzed different *Gata2* regulatory regions ([Fig. 3 A](#fig3){ref-type="fig"}) for their capacity to respond to ectopically expressed ICN1 or HES-1. We found that *Gata2p-IS*, containing RBPJ sites, but not *Gata2p-IG,* was transcriptionally induced by the Notch coactivator Mam1 in a dose-dependent manner and repressed by a dominant-negative RBPJ ([Fig. 3 B](#fig3){ref-type="fig"}). Furthermore, *Gata2p-IS* promoter was activated two- to fourfold by ICN1 after inhibition of endogenous Notch activity by DAPT ([Fig. 3 B](#fig3){ref-type="fig"} and not depicted). By mutational analysis, we found that both predicted RBPJ-binding sites in the *Gata2p-IS* promoter were functional because only elimination of the two sites impaired the capacity of this reporter to be activated by Notch ([Fig. 3 C](#fig3){ref-type="fig"}). In similar experiments, *Gata2p-IG* reporter was repressed by ectopic HES-1 expression and activated in cells transduced with *Hes1*-specific shRNA ([Fig. 3, D and E](#fig3){ref-type="fig"}). Mutational analysis demonstrated that all three HES-binding sites were functional and sufficient to repress *Gata2* reporter expression because only the combined mutation of all three sites relieved *Gata2* repression by HES-1 ([Fig. 3 E](#fig3){ref-type="fig"}). As we previously showed that Jagged1 is the Notch ligand required in the AGM for the hematopoietic development ([@bib32]), we next measured the levels of *IS* and *IG Gata2* mRNA in AGM from embryos deficient for Jagged1 by qRT-PCR and found that both transcripts are equally down-regulated in the absence of Notch activation ([Fig. 3 E](#fig3){ref-type="fig"}). Moreover, we detected a similar significant increase of both *IS* and *IG* mRNA in the AGM from *Hes*-deficient embryos, suggesting that Notch and HES are globally affecting the *Gata2* locus. Together, these results indicate that Notch and HES coregulate expression of the *Gata2* promoter in vitro in an opposite manner.

![**HES-1 is a negative regulator of the *Gata2* promoter in hematopoietic cells.** (A) Scheme of the *Gata2* locus indicating the conserved RBPJ- and HES-binding sites (vertical arrows). Promoter regions were used in the luciferase assay. (B) Luciferase activity from the *Gata2p-IS* and *Gata2p-IG* promoter in the presence or absence of ICN1, Mam1, or dn-RBP in HEK-293T cells (\*\*, P ≤ 0.009). The dotted line in the Western blot (WB) indicates that intervening lanes have been spliced out. (C) Luciferase activity from the *Gata2-IS* promoter with indicated point mutations in the RBPJ-binding consensus (bold/underlined) measured in HEK-293T cells. DAPT incubation was used to reduce endogenous Notch activity. (D) Luciferase activity of the *Gata2-IG* promoter in the presence or absence of HES-1. (E) Luciferase activity from the *Gata2-IG* promoter with the indicated point mutations (bold/underlined) in the HES-binding consensus. (B--E) Mean ± SD of at least three independent experiments is shown in all the plots; Student's *t* test was used to assess the significance (\*, P \< 0.05). (F) Relative expression of the indicated genes from independent determinations of fresh E10.5 AGMs in *Jagged1^+/+^* (*n* = 3) and *Jagged1^−/−^* (*n* = 3) and E10.5 AGMs in *Hes1-5* wild type (*n* = 2) and knockouts (*n* = 3) by qRT-PCR after 3 d of 4-OH-tamoxifen treatments in explant cultures. Fold increase to the wild-type control after *GAPDH* normalization is shown. Bars represent the mean ± SD determination; Student's *t* test was used to assess the significance (\*, P \< 0.05).](JEM_20120993_Fig3){#fig3}

Notch/RBPJ and HES control *Gata2* expression during embryonic development
--------------------------------------------------------------------------

To test whether Notch and HES control *Gata2* expression in the embryo, we generated point mutations for both RBPJ sites (*p7.0IS RBP12*) on the previously characterized *Gata2-IS* reporter construct (*p7.0IS WT*; [Fig. 4 A](#fig4){ref-type="fig"}; [@bib25], [@bib26]) and microinjected mutant or wild-type DNA into fertilized oocytes. The expression patterns of GFP driven by these promoters in the transgenic F~0~ (founders) mice were examined at E10.5 ([Fig. 4 B](#fig4){ref-type="fig"}). In embryos carrying the wild-type reporter, we found specific expression of GFP in the dorsal aorta and neural tissue (3/4 transgene-positive embryos as determined by PCR) as previously reported ([@bib26]). Importantly, mutations in the core of the RBPJ-binding sites abolished the expression of the reporter gene in both the aorta and the neural tissue (0/9 transgene-positive embryos by PCR). Immunostaining with anti-GFP in embryo sections confirmed the expression pattern for the *Gata2* reporter in wild-type embryos and the absence of GFP in the aorta or neural tube of embryos carrying the RBPJ mutant reporter ([Fig. 4 C](#fig4){ref-type="fig"}). These results indicate that Notch/RBPJ activity is required for driving *Gata2* transgene expression from the *IS* promoter in both hematopoietic and neural tissues. We performed comparable experiments using the *p4.0* reporter with mutations of all three HES sites. This reporter contains the −4 to 5 kb sequence of the mouse *Gata2* locus (including *IS* and *IG* promoter regions) and recapitulates the expression pattern of the endogenous *Gata2* gene in transgenic embryos (including expression in the AGM and neural tube; [@bib25], [@bib26]). Based on our in vitro data, we predicted that HES-binding site mutations might either increase the reporter levels within a particular cell population or change the cell type specificity of the reporter. Therefore, as readout for these experiments, we determined GFP levels in specific hematopoietic (CD31^+^/C-Kit^+^CD45^+^), prehematopoietic (CD31^+^C-Kit^+^CD45^−^), and endothelial (CD31^+^C-Kit^−^CD45^−^) cell populations from E9.5--10.5 transgenic embryos (26--35 somite pairs). Our results demonstrate that the wild-type reporter was expressed at low levels in all the AGM subpopulations. Interestingly, HES mutant reporter led to an increased percentage of GFP-positive cells that was not significant in the endothelial lineage (from 8 ± 2.6% to 18.1 ± 4.6%; P = 0.07) or in the committed HSC and progenitors (HSC/Ps; from 6 ± 3% to 24 ± 16%; P = 0.13) but reached statistical significance in the prehematopoietic population (from 6.2 ± 4.6% to 38 ± 10%; P = 0.015; [Fig. 4, D and E](#fig4){ref-type="fig"}). Moreover, hematopoietic cells carrying the mutant reporter showed increased expression levels of GFP ([Fig. 4, D and F](#fig4){ref-type="fig"}). These results demonstrate that Notch is required for *Gata2* expression in the AGM, whereas HES restricts the levels of *Gata2* specifically within the presumptive AGM hematopoietic cells.

![**Notch/RBPJ and HES-1 regulate *Gata2* promoter in vivo during embryonic development.** (A) Schematic representation of the *Gata2* promoter constructs analyzed in vivo. (B) Representative brightfield (left) and fluorescent (right) micrographs of embryos containing the wild-type or RBPJ mutant *Gata2p7.0IS* construct at E10.5. Arrowheads indicate the structures (FL, fetal liver; me, mesencephalon). Summary of the data from at least three independent experiments is indicated at the bottom. Fisher test was used to assess the significance. (C) Transversal section of the AGM region and neural tube (nt) of E10.5 embryos containing the indicated constructs showing expression of GFP as detected by immunostaining. Nuclear staining by DAPI is represented in blue. Arrowheads indicate the structures (Ao, aorta; IAHC, intra-aortic hematopoietic cluster; m, mesonephros; p2, neural tube p2 domain). Bars: (B) 2 mm; (C) 200 µm. (D) Flow cytometry analysis of GFP in the indicated CD31^+^ subpopulation of E10.5 AGM cells from two representative embryos containing the *p4.0* wild-type or mutant for HES sites. (E and F) Mean percentage (E) and mean intensity (F) of GFP^+^ cells in the endothelial (CD31^+^C-Kit^−^CD45^−^), prehematopoietic (CD31^+^C-Kit^+^CD45^−^), and HSC/P (CD31^+^C-Kit^+^CD45^+^) populations from three transgene-positive embryos from at least two independent experiments (\*\*, P = 0.01). Error bars represent SEM.](JEM_20120993_Fig4){#fig4}

AGM hematopoietic clusters in Hes-deficient embryos lack functional progenitors and HSCs
----------------------------------------------------------------------------------------

We have shown that *Hes* deficiency results in enlarged hematopoietic clusters in the developing AGM. To test the functionality of these mutant hematopoietic cells, we used the mouse line containing the tamoxifen-inducible *β-actin--CRE-ERT* transgene in different combinations of the *loxP-Hes1* and the *Hes5* deleted alleles. E10.5 AGMs of the different genotypes were dissected and cultured as explants for 3 d in the presence of 4-OH-tamoxifen to induce the deletion. Dissociated AGM cells were then plated in methylcellulose to determine the number of hematopoietic progenitors by colony-forming cell (CFC) assays. We found that AGM cells containing three deleted *Hes* alleles showed significantly different number of functional progenitors (CFC) when compared with those carrying one or two deleted alleles ([Fig. 5 A](#fig5){ref-type="fig"}). These results suggest that a minimum threshold of HES levels (two wild-type alleles) is required to maintain the functionality of hematopoietic progenitors. Interestingly, CFC assay of E10.5 YS cells revealed that progenitors contained in the extraembryonic tissue are not significantly affected in the *β-actin--CRE-ERT loxP-Hes1* R26-YFP^f/+^ *Hes5^+/−^* embryos (not depicted), in agreement with previous findings showing the Notch-independent formation of YS progenitors ([@bib31]; [@bib2]). Analysis of the colonies by PCR confirmed the deletion of the inducible alleles after tamoxifen treatment ([Fig. 5 A](#fig5){ref-type="fig"}). Furthermore, hematopoietic progenitors (defined as CD34^+^C-Kit^+^) isolated from constitutive *Hes1^−/−^Hes5^−/−^* embryos were unable to produce sca1^+^C-Kit^+^ progenitors and CD45^+^ hematopoietic cells when cultured on OP9 stroma, compared with Hes5^−/−^ cells ([Fig. 5 B](#fig5){ref-type="fig"}).

![**AGM hematopoietic clusters in Hes-deficient embryos lack functional progenitors and HSCs.** (A) Determination of CFU-C hematopoietic progenitors obtained from E10.5 AGM after 3 d of explant culture in the presence of 4-OH-tamoxifen to induce *Hes1* deletion. Kruskal--Wallis and Mann--Whitney *U* tests were used to assess the significance. Mean ± SEM from three or more AGM explants from at least three independent experiments is shown. PCRs from isolated colonies to test *Hes1* deletion are shown. (B) Flow cytometry analysis from CD34^+^C-KIT^+^ sorted cells from E9.5 and E10.5 embryos with the indicated genotypes cultured on OP9 with factors (SCF^+^IL3^+^Epo^+^G-CSF) for 10 d. Dot plots are representative of three independent experiments. (C) Spleen colonies from 4-OH-tamoxifen--treated E10.5 AGM explants from the indicated genotypes injected in irradiated SCID-Beige mice. Mean of (CFU-S~11~) from three or more injected animals is shown. Student's *t* test was used to assess significance. Error bars represent the mean of colonies in the spleens analyzed. (D) Representative spleen images (top) and PCR from dissected spleen colonies to test for *Hes1* deletion (bottom) are shown. (E) Flow cytometry analysis at 2 mo of SCID-Beige transplanted animals. Each mouse was transplanted with 2 ee AGMs after 3 d of 4-OH-tamoxifen treatments in explant culture. Two representative controls (*n* = 4) and two *Hes1^f/f^Hes5^+/−^* *R26-YFP^f/+^* *β-actin--CRE-ERT* (*n* = 3) are shown. Controls with \>1% of YFP cells were considered as reconstituted. (F) Quantification of Ki67 and TUNEL within the CD31-positive cells from immunostainings (*n* = 2 each genotype) of Ki67/CD31 and TUNEL/CD31 in the AGM region in wild-type or *Hes1^f/f^Hes5^−/−^* *β-actin--CRE-ERT* mutant embryos after in vivo tamoxifen induction at day E8. Error bars represent the mean of positive cells from the different embryos analyzed. (G) Gating strategy to analyze the different subpopulations by flow cytometry analysis of fresh E10.5 AGMs with functional HSC phenotype (zero to one *Hes* deleted alleles; *n* = 4) or with nonfunctional HSC phenotype (three to four *Hes* deleted alleles; *n* = 3) after in vivo 4-OH-tamoxifen induction at E8. (H) Bars represent the mean percentage ± SD of positive cells of the indicated populations.](JEM_20120993_Fig5){#fig5}

To measure the number and functionality of *Hes*-deficient hematopoietic progenitors in an in vivo system, we determined the capacity of dissociated AGM cells from tamoxifen-treated explants of different genotypes to generate spleen colonies (CFU-S~11~) in lethally irradiated mice. As *Hes1^f/f^Hes5^−/−^* mutant animals were obtained on a mixed background, we used immunodeficient SCID-Beige mice as recipients for the transplants to avoid graft rejection. In these experiments, we obtained a mean number of 16.6 ± 1.4 CFU-S~11~ from one wild-type E10.5 AGM explant (1 embryo equivalent \[1 ee\]), similarly to that obtained from *Hes5^−/−^* AGM explants ([Fig. 5, C and D](#fig5){ref-type="fig"}; and not depicted). In contrast, the number of colonies obtained from AGM explants with all four *Hes* alleles deleted was comparable with the noninjected/irradiated controls (4 ± 0.3; [Fig. 5, C and D](#fig5){ref-type="fig"}), and the few colonies detected did not contain *Hes1* deletion ([Fig. 5 D](#fig5){ref-type="fig"}, bottom). We next determined the existence of functional HSCs after induction of Hes1 deletion in E10.5 AGM explants from the *β-actin--CRE-ERT loxP-Hes1* R26-YFP^f/+^ *Hes5^+/−^* background compared with the *β-actin--CRE-ERT* R26-YFP^f/+^. To increase the repopulating capacity of E10.5 AGM, we injected 2 ee per each SCID-Beige recipient together with spleen cells as a support. In these experiments, we did not detect any HSC activity from Hes-deficient AGM cells (three alleles deleted), whereas all mice transplanted with control cells showed hematopoietic multilineage reconstitution after 8 wk (*n* = 4, considering \>1% of donor cells in peripheral blood; [Fig. 5 E](#fig5){ref-type="fig"} and not depicted).

Although these results indicate that E10.5 *Hes*-deficient embryos (deletion induced in vivo at E8.5) do not contain functional HSC/Ps, their AGMs contained higher numbers of CD41^+^ and C-Kit^+^ cluster cells ([Fig. 1, F--H](#fig1){ref-type="fig"}; and not depicted). To further understand how *Hes* deficiency contributes to this particular phenotype, we determined by immunofluorescence the number of TUNEL- and Ki67-positive cells in the CD31^+^ cells of sections from E10.5 wild-type and *β-actin--CRE-ERT loxP-Hes1Hes5^−/−^* embryos treated with tamoxifen at E8.5. We found that CD31^+^ cells of the AGM contain a significantly higher number of Ki67^+^ cells and very low but comparable numbers of TUNEL^+^ cells ([Fig. 5 F](#fig5){ref-type="fig"}). Most importantly, a detailed analysis of the different subpopulations contained within the CD31^+^ population of the AGM (hematopoietic clusters plus endothelium) demonstrated that whereas the C-Kit^+^CD41^+^CD45^−^ (pre-HSC) population was increased upon *Hes* deletion, the C-Kit^+^CD41^+^CD45^+^ population that defines the committed HSCs was significantly decreased ([Fig. 5, G and H](#fig5){ref-type="fig"}). These results suggest that Hes deficiency induces higher proliferation in the AGM clusters while preventing prehematopoietic cells to reach the HSC stage.

Reduction of Notch signaling partially rescues the Hes-dependent hematopoietic defect
-------------------------------------------------------------------------------------

To investigate the putative connection between overexpression of *Gata2* and overproduction and nonfunctional hematopoietic cells in the AGM, we aimed to reduce *Gata2* levels in the Hes-deficient AGM cells. Because *Gata2* expression is dependent on Notch activity, we anticipated that incubation of *Hes*-deficient cells with limited concentrations of Notch/γ-secretase inhibitors should lead to a decrease of *Gata2* levels that would be compatible with the hematopoietic development.

After testing different DAPT concentrations, we found that incubation of *Hes*-deficient AGM cells in liquid cultures containing 0.05 µM DAPT resulted in a substantial decrease of *Gata2* levels, resembling the levels detected in DMSO-treated wild-type AGM cells ([Fig. 6 A](#fig6){ref-type="fig"}). In these conditions, *Hes*-deficient AGM cultures produced increased numbers of CD45^+^ cells compared with the DMSO-treated *Hes*-deficient cultures ([Fig. 6 B](#fig6){ref-type="fig"}). Conversely, incubation of wild-type AGM cells with the same dose of DAPT (or higher) resulted in a decrease in CD45^+^ cell production as previously published ([@bib32]). These results indicate that the positive hematopoietic effect of DAPT observed in *Hes*-deficient cells is not directly mediated by changes in Notch activity but by a downstream target of Notch and Hes. Based on this data, we propose the existence of a permissive threshold of *Gata2* levels that is acquired by the combined action of Notch and Hes repressors that allow hematopoietic development in the AGM (see model in [Fig. 6 C](#fig6){ref-type="fig"}). Together, these results indicate that HES proteins are responsible for the control of *Gata2* levels downstream of Notch signaling, which is essentail for the generation of HSCs during embryonic development.

![**Reduction of Notch signaling partially rescues Hes-dependent hematopoietic defect.** (A) Wild-type and *Hes1^f/f^Hes5^−/−^* *β-actin--CRE-ERT* E10.5 dissected AGMs after in vivo tamoxifen induction at E8.5, disrupted with collagenase, and plated in liquid culture in the presence of cytokines (IL6, IL3, and SCF), DMSO, or 0.05 µM DAPT; mRNA was obtained to quantify the levels of *Gata2* after 24 h. Bars represent the mean ± SD determination (*n* = 3 each condition). (B) In parallel, cultures were analyzed after 6 d by flow cytometry to quantify the amount of cells CD45^+^ (wild type, *n* = 4; *Hes1^f/f^Hes5^−/−^* *β-actin--CRE-ERT*, *n* = 10). (C) In the presence of HES-1, *Gata2* levels are limited to the just-right dose to generate functional HSC/P. (D) In the absence of *Hes1*, *Gata2* levels cannot be repressed and result in the generation of a great number of nonfunctional progenitors.](JEM_20120993_Fig6){#fig6}

DISCUSSION
==========

Deciphering the molecular events that control hematopoietic development is a crucial issue for understanding how functional HSCs are produced and maintained. In this work, we focused on the role of HES proteins, which are the principal mediators of the Notch pathway in multiple systems.

Fetal liver of *Hes1*-deficient embryos had been previously analyzed, and no major defects on HSC activity were found ([@bib36]), although a direct measure of HSC activity was not performed. Importantly, here we demonstrate that *Hes5* (which is functionally equivalent to *Hes1*) is expressed de novo in the aorta of *Hes1* mutants, which suggests the possibility of functional compensation between both proteins. In agreement with this, we found that cumulative deletion of *Hes1* and *Hes5* alleles leads to the generation of nonfunctional hematopoietic progenitors in the developing AGM and the total absence of HSC activity. In addition, we demonstrate that the *Gata2* gene is directly activated by Notch/RBPJ but repressed by HES-1 specifically in the C-Kit^+^ cell population of the emerging AGM clusters. Thus, in *Hes*-deficient mutants, *Gata2* is up-regulated, and the number of hematopoietic cluster cells increased, but they only contained nonfunctional hematopoietic cells, in agreement with previous work demonstrating that *Gata2* levels need to be tightly regulated to generate and maintain functional HSCs ([@bib21]; [@bib34]). Our experiments show that limiting Notch activity in the absence of HES can decrease the levels of *Gata2* and partially restore the hematopoietic production from AGM cells. Mechanistically, one possibility is that overexpression of *Gata2* in AGM cells imposes an impairment to cell cycle entry in the hematopoietic progenitor populations, as it was demonstrated in the cord blood HSCs ([@bib35]); however, our results indicate that the *Hes*-deficient endothelium contains more proliferative cells, suggesting that AGM subpopulations may show specific response to different GATA-2 levels.

Analysis of the Gata2 regulatory regions led to the identification of two functional DNA-binding sites for Notch/RBPJ and three for HES, and we demonstrated their relevance in the activation and repression of this gene in the embryonic aorta, the niche of nascent HSCs. As *Hes* is robustly induced by Notch, activation of this pathway in the hematopoietic progenitors might induce both positive and negative signals in the *Gata2* gene, resulting in the so-called type I incoherent feed-forward loop (I1-FFL; [@bib22]), which from our predictions would limit *Gata2* activation in this tissue ([Fig. 6 A](#fig6){ref-type="fig"}). These types of circuits have previously been found to regulate Notch-dependent cell fate decisions in *Drosophila* ([@bib19]). Here, we propose that after Notch activation, likely through Jagged1, *Gata2* and *Hes* genes start to be transcribed until HES protein reaches the threshold for repressing the *Gata2* promoter. Then *Gata2* transcription decreases, and its mRNA and protein concentration drops, resulting in a pulse-like dynamic that it is required to achieve limited/transient (producing functional progenitors) rather than high/sustained activation (producing nonfunctional progenitors; see model in [Fig. 6 B](#fig6){ref-type="fig"}). I1-FFLs are also known to regulate biphasic responses where the output levels (in this case *Gata2*) depend on the input dose (Notch intensity; [@bib15]). By computer modeling, it has been demonstrated that I1-FFLs regulate time- or dose-dependent biphasic behaviors in a mutually exclusive manner ([@bib15]), and further work is needed to address whether *Gata2* regulation by Notch and HES follows one of these two models. In this work, we have dissected the effects of a single Notch pathway mediator (HES) during the generation of HSCs. However, this is an extremely simplified picture of the Notch-dependent regulatory networks occurring during this process, and many other elements and pathways will be sequentially incorporated into the final model. One example is the restriction imposed by the availability of Notch ligands to the Notch-responding cell that will depend on other upstream signals such as WNT ([@bib8]; [@bib33]), the specificity of Notch for its ligands that is modulated by Fringe-mediated glycosylation ([@bib17]), or other interactions with the niche, which will be crucial to achieve the proper intensity of Notch signal in individual AGM cells. Another variable is HES-1 protein stability, which is regulated by the JAK--STAT pathway and directly impacts HES oscillation ([@bib40]). In addition, *Hes1* transcription itself is controlled by a negative autoregulatory feedback loop ([@bib12]). Finally, a complex network of interactions that involves FLI1 and SCL and operates downstream of Notch and GATA-2 in the HSC and hematopoietic precursors has already been modeled ([@bib28]). In summary, we have here deciphered the first mechanism downstream of Notch signaling that regulates HSC development.

MATERIALS AND METHODS
=====================

### Animals.

CD1, C57B6/J wild-type, and *Jagged1^−/−^* ([@bib39]), *Hes1^−/−^*;*Hes5^−/−^* ([@bib29]), *Hes1^f/f^* ([@bib13]), and *β-actin--CRE-ERT* ([@bib11]) strains were used. *R26-RYFP^f/f^* (strain name: B6.129X1-*GT(ROSA)26Sor^tm1(EYFP)Cos^/*J) was obtained from the Jackson Laboratory. C57BL6/J oocytes were used in F~0~ assays. SCID-Beige animals were used as recipients in CFU-S~11~ and long-term reconstitution experiments. Animals were kept under pathogen-free conditions, and all procedures were approved by the Animal Care Committee of the Parc de Recerca Biomèdica de Barcelona (regulation of Generalitat de Catalunya). Embryos were obtained from timed pregnant females and staged by somite counting: E10.5 (31--40 sp). The detection of the vaginal plug was designated as day 0.5. Mice and embryos were all genotyped by PCR.

### qRT--PCR.

Total RNA was extracted with a QIAGEN kit, and RT-First Strand cDNA Synthesis kit (GE Healthcare) was used to produce cDNA. qRT-PCR was performed in a LightCycler480 system using SYBR Green I Master kit (Roche). Primers used are in [Table S1](http://www.jem.org/cgi/content/full/jem.20120993/DC1){#supp1}.

### Promoter analysis, site-directed mutagenesis, and luciferase assays.

Human and mouse *Gata2* promoters were analyzed using Genomatix software. For luciferase assays, *Gata2p-IG* was previously described ([@bib24]), which covers from −482 of *IG* transcript to exon 2. *Gata2p-IS* was generated cloning the region from −794 to 93 of exon *IS* into the pGL3 vector and verified by sequencing. The primers used were Fwd (5′-AAAACTCGAGGGTGCTACAAGGATGTGGTTGC-3′) and Rev (5′-AAAAAAGCTTGCTATGGTTGAGGTGATCTTAGGC-3′). Mutations were introduced into wild-type plasmids using the QuikChange Site-Directed Mutagenesis kit from Agilent Technologies according to the manufacturer's instructions. The mutations introduced and primers used are specified in [Table S2](http://www.jem.org/cgi/content/full/jem.20120993/DC1){#supp2}. All mutations were verified by DNA sequencing.

Luciferase reporter assays were performed in HEK-293T cells. Cells were seeded in 12-well plates at a density of 5 × 10^4^ cells/well. Equal amounts (150 ng) of the different *Gata2* reporter constructs *ICN1*, *Mastermind*, *dn-Rbpj*, *shHes1* (MISSION, TRCN0000018989), or irrelevant DNA and 150 ng CMV--*β-Galactosidase* plasmids were transfected in triplicate wells. Cells were transfected using polyethylenimine (PEI; Polysciences, Inc.). To reduce endogenous ICN1 levels, HEK-293T cells were treated with γ-secretase inhibitor, DAPT (EMD), at 50 µM final concentration for 72 h before transfection and during the assay. Luciferase was measured after 48 h of transfection according to the manufacturer's instructions (Luciferase Assay System; Promega). Expression levels of transfected proteins were verified by Western blot.

### ChIP assay.

Chromatin was obtained from a pool of 40 dissected AGMs at E10.5 or 32D myeloid progenitor cells line. ChIP was performed as previously described ([@bib1]) with minor modifications. In brief, cross-linked chromatin from E10.5 dissected AGMs or 32D cell line was sonicated for 10 min, medium-power, 0.5-interval, with a Bioruptor (Diagenode) and precipitated with anti-RBPJ ([@bib5]), anti-ICN1 (Abcam), and anti-HES1 (H-20 from Santa Cruz Biotechnology, Inc. and N terminus from Aviva Systems Biology). After cross-linkage reversal, DNA was used as a template for PCR. RT-PCR was performed with SYBR Green I Master (Roche) in a LightCycler480 system. Primers used are in [Table S3](http://www.jem.org/cgi/content/full/jem.20120993/DC1){#supp3}.

### Cell culture, viral particle production, and viral infection.

32D cells were cultured in Iscove's and 10% FBS supplemented with 10% WeHi-IL3--conditioned media. HEK-293T cells were seeded at a density of 5 × 10^5^ cells/well and transfected with ICN1-IRES-GFP with PEI. Hematopoietic cells from disrupted AGMs were incubated in Iscove's, 10% FBS, 10% IL-3, and 10% stem cell factor (SCF)--conditioned medium plus 0.2 µg/ml IL6 and 0.1 µg/ml Flt3. To assess hematopoietic potential of sorted populations from *Hes1^−/−^Hes5^−/−^* mutant mice, 500 CD34^+^C-Kit^+^ cells were FACS purified and added to confluent cultures of OP9 stromal cells and cultured for up to 10 d in the presence of 100 ng/ml IL-3, 100 U/ml SCF, 100 ng/ml G-CSF, and 200 ng/ml erythropoietin (Epo). Supplemented differentiation medium was replaced every 4 d. Cultures were maintained for up to 12 d. Cells were harvested by pipetting and examined for hematopoietic development by flow cytometry.

### Flow cytometry analysis and sorting.

The AGM region was dissected from E10.5 embryos and dissociated in 0.12% collagenase (Sigma-Aldrich) in PBS supplemented with 10% FBS for 30 min at 37°C. The cells were analyzed by flow cytometry in a FACSCalibur (BD) or FACSAria (BD) and FlowJo software (Tree Star). Dead cells were excluded by 7-aminoactinomycin-D staining (Molecular Probes) in the FACSCalibur analysis and with Hoechst or DAPI in the FACSAria analysis. The YSs and lower trunk regions were harvested from individually dissected embryos washed of maternal blood ([@bib10]). The anterior regions were used for genotyping ([@bib29]). YSs and lower trunk regions were dissociated with 0.1% wt/vol collagenase types I and IV (Sigma-Aldrich) for 1 h at 30°C. Cells were then blocked with normal mouse serum and incubated with fluorescence-conjugated antibodies. For flow cytometric analysis, cells were resuspended in Hank's buffered Saline Solution (Gibco) containing propidium iodide (Sigma-Aldrich) for dead cell exclusion. Flow cytometry was performed using a FACSVantage (BD) with CellQuest (BD), and data were analyzed using the FlowJo software package. The antibodies CD31-PE, Sca1-PE, CD45-FITC, Ter119-PE, CD45-PerCPCy5.5, and CD117-APC were purchased from BD and CD41-PeCy7 from eBioscience. VE-cadherin--APC was generated in-house.

### Immunostaining.

E10.5 embryos were fixed overnight in 4% paraformaldehyde (Sigma-Aldrich) at 4°C and frozen in Tissue-Tek (Sakura). 5-µm sections were fixed with −20°C methanol for 15 min and block permeabilized in 10% FBS, 0.3% Surfact-AmpsX100 (Thermo Fisher Scientific), and 5% nonfat milk in PBS for 90 min at 4°C. Samples were stained with CD31 (PECAM1 at 1:50; BD) or CD41 (1:50; BD) or C-Kit (CD117 at 1:50; BD) in 10% FBS, 5% nonfat milk in PBS overnight, and HRP-conjugated secondary antibody (Dako) at 1:100 for 90 min and developed with Cy3 or coupled tyramide (PerkinElmer). Anti-GFP (MBL) was used at 1:100, and Alexa Fluor 488--conjugated donkey anti--rabbit (1:500; Invitrogen) was used as a secondary antibody. DeadEnd Fluorimetric System (Promega) and Ki67 (1:500; Novocastra) were also used. Sections were mounted in Vectashield medium with DAPI.

### In situ hybridization.

For in situ hybridization, precisely timed embryos were fixed overnight at 4°C in 4% paraformaldehyde and embedded in OCT (Tissue-Tek). Embryos were sectioned in an RM2135 cryostat (Leica) at 16 µm. Digoxigenin-labeled probes were generated from a Bluescript plasmid (Agilent Technologies) containing a partial mouse *Gata2* cDNA (nt 170--871) and from plasmid containing *Hes1* cDNA and *Hes5* cDNA. Images were acquired with a BX-60 (Olympus). Representative images were edited on Photoshop CS4 software (Adobe).

### Transgenic mice: F~0~ assays.

*Gata2* promoter inserts from plasmids (*p4.0*, *p4.0 muHes*, *p7.0*, and *p7.0 muRBP*) were purified by NACS PREPAC (Gibco), adjusted to 5--10 ng/ml, and injected into mouse oocytes using standard strategies. Transgene integration was confirmed by PCR from genomic DNA from embryonic tissues. The wild-type constructs *p4.0* ([@bib16]) and *p7.0* ([@bib25]) were previously described, and point mutations were introduced into these plasmids.

### AGM explant culture.

The AGM region was dissected and cultured in explants for 3 d as previously described ([@bib23]). In brief, AGMs were deposited on nylon filters (EMD Millipore) placed on metallic supports and cultured in myeloid long-term culture medium (STEMCELL Technologies) supplemented with 10 µM hydrocortisone (Sigma-Aldrich) in an air-liquid interphase. The induction of *β-actin--CRE-ERT* transgene was performed by adding 4-OH-tamoxifen (Sigma-Aldrich) every 36 h to the explant medium at a final concentration of 1 µM.

### Hematopoietic colony assay (CFU-C) and CFU-S~11~ and long-term reconstitution assay.

The explanted AGMs were digested in 0.12% collagenase (Sigma-Aldrich) in PBS supplemented with 10% FBS for 20 min at 37°C and used for hematopoietic colony assay (CFU-C), CFU-S~11~, and long-term reconstitution assay experiments. In CFU-C assay, 20,000 cells/AGM were plated in duplicates in M-3434 semisolid medium (STEMCELL Technologies). After 7 d, the presence of hematopoietic colonies was scored under the microscope. In CFU-S~11~ experiments, whole disrupted AGMs were injected intravenously in SCID-Beige recipients. SCID-Beige recipients were previously irradiated at 2.5 Gy. After 11 d, the presence of colonies in the spleen was scored under the stereoscope. Some colonies were picked and lysed in 0.01 M Tris, pH, 7.4, 0.15 M NaCl, 0.01 M EDTA, and 0.5% SDS. From this lysate, *Hes1* deletion was detected in both types of colonies, CFU-C and CFU-S~11~, by PCR (primers in [Table S4](http://www.jem.org/cgi/content/full/jem.20120993/DC1){#supp4}). In long-term reconstitution assay experiments, whole disrupted AGMs were injected intravenously in SCID-Beige recipients, with 500,000 white spleen cells from a SCID-Beige animal as support cells. SCID-Beige recipients were previously irradiated at 2.5 Gy.

### Statistics.

Statistical analyses were performed using Excel 2011 (Microsoft) and SPSS. In [Fig. 3 (B--D)](#fig3){ref-type="fig"}, [Fig. 4 E](#fig4){ref-type="fig"}, and [Fig. 5 D](#fig5){ref-type="fig"}, statistical significance was assessed using two-tailed Student's *t* tests. In [Fig. 1 (F and G)](#fig1){ref-type="fig"} and [Fig. 2 A](#fig2){ref-type="fig"}, statistical significance was assessed using the Spearman test. In [Fig. 4 A](#fig4){ref-type="fig"}, statistical significance was assessed using the Fisher test. In [Fig. 5 A](#fig5){ref-type="fig"}, Kruskal--Wallis and Mann--Whitney *U* tests were used to assess the significance. In all tests, p-values \< 0.05 were considered significant. In all experiments: \*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.001.

### Online supplemental material.

Table S1 lists mouse RT-PCR primers. Table S2 lists mutagenesis primers. Table S3 lists mouse ChIP primers. Table S4 lists *Hes1* lox-P sites to detect deleted bands. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20120993/DC1>.
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